Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

By G. Bloomgren, S. Richman, C. Hotermans, M. Subramanyam, S. Goelz, A. Natarajan, Sophia Lee, T. Plavina, J. Scanlon, A. Sandrock and 1 more. New England Journal of Medicine, 2012

1,184 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/fff732605db8385c3b5aeb57f7bafdde169b6174

Citations in the corpus

• The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016, neutral): “Patients exposed to vedolizumab, n (%) ≥1 dose 1077 (97) 1712 (97) 2789 (97) ≥6 months 837 (75) 1163 (66) 2000 (69) ≥12 months 574 (52) 827 (47) 1401 (49) ≥18 months 473 (42) 677 (38) 1150 (40) ≥24 months 428 (38) 478 (27) 906 (31) ≥36 months 198 (18) 209 (12) 407 (14) ≥48 months 30 (3) 10 (1) 40 (1”